*In adult patients undergoing surgical procedures with either neuraxial [[anesthesia]] or [[general anesthesia]]:
:*50 mcg to 250 mcg by intravenous bolus administration. The most frequently reported initial bolus dose is 50 mcg or 100 mcg.
:*0.5 mcg/kg/min to 1.4 mcg/kg/min by intravenous continuous infusion, titrated to blood pressure goal.
=====Septic or Other Vasodilatory Shock=====
*No bolus.
*0.5 mcg/kg/min to 6 mcg/kg/min by intravenous continuous infusion, titrated to [[blood pressure]] goal. Doses above 6 mcg/kg/min do not show significant incremental increase in blood pressure.
=====Uveitis=====
*Posterior Synechiae: Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be used in patients with [[uveitis]] when synechiae are present or may develop. The formation of synechiae may be prevented by the use of this solution and atropine or other [[cycloplegics]] to produce wide dilation of the pupil. For recently formed posterior [[synechiae]] one drop of Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be applied to the upper surface of the cornea and be repeated as necessary, not to exceed three times. Treatment may be continued the following day, if necessary. Atropine sulfate and the application of hot compresses should also be used if indicated.
=====Glaucoma=====
*Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be used with miotics in patients with open angle glaucoma. It reduces the difficulties experienced by the patient because of the small field produced by [[miosis]], and still it permits and often supports the effect of the miotic in lowering the intraocular pressure in open angle glaucoma. Hence, there may be marked improvement in visual acuity after using Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% in conjunction with miotic drugs.
=====Mydriasis Induction=====
*Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be used effectively to increase [[mydriasis]] with homatropine hydrobromide, [[cyclopentolate]] hydrochloride, [[tropicamide]] hydrochloride and atropine sulfate.
*One drop of the preferred cycloplegic is placed in each eye, followed in 5 minutes by one drop of Phenylephrine Hydrochloride Ophthalmic Solution, 2.5%. Since adequate [[cycloplegia]] is achieved at different time intervals after the instillation of the necessary number of drops, different cycloplegics will require different waiting periods to achieve adequate [[cycloplegia]].
<!--Off-Label Use and Dosage (Adult)-->
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Hypotension, During anesthesia; Prophylaxis=====
*In women undergoing elective cesarean section with [[spinal anesthesia]], phenylephrine reduced the incidence of [[hypotension]] when used with ephedrine as prophylaxis.<ref name="pmid11575540">{{cite journal| author=Mercier FJ, Riley ET, Frederickson WL, Roger-Christoph S, Benhamou D, Cohen SE| title=Phenylephrine added to prophylactic ephedrine infusion during spinal anesthesia for elective cesarean section. | journal=Anesthesiology | year= 2001 | volume= 95 | issue= 3 | pages= 668-74 | pmid=11575540 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11575540 }} </ref>
*0.2 to 0.4 mg phenylephrine.<ref name="pmid884795">{{cite journal| author=Waxman MB, Wald RW| title=Termination of ventricular tachycardia by an increase in cardiac vagal drive. | journal=Circulation | year= 1977 | volume= 56 | issue= 3 | pages= 385-91 | pmid=884795 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=884795 }} </ref>
=====Priapism=====
*1 mg phenylephrine bolus followed by continuous intracavernosal phenylephrine infusion of 2 mg/hour.<ref name="pmid2627645">{{cite journal| author=Buckley JF, Chapple CR, McNicholas T| title=Continuous infusion of phenylephrine in the treatment of papaverine-induced priapism. | journal=Br J Urol | year= 1989 | volume= 64 | issue= 6 | pages= 654-5 | pmid=2627645 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2627645 }} </ref>
=====Regional anesthesia; Adjunct=====
*Phenylephrine 0.125% to combinations of tetracaine 0.5% plus glucose 7.5% or 0.75%.<ref name="pmid8922770">{{cite journal| author=Sumi M, Sakura S, Sakaguchi Y, Saito Y, Kosaka Y| title=Comparison of glucose 7.5% and 0.75% with or without phenylephrine for tetracaine spinal anaesthesia. | journal=Can J Anaesth | year= 1996 | volume= 43 | issue= 11 | pages= 1138-43 | pmid=8922770 | doi=10.1007/BF03011841 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8922770 }} </ref>
<!--Pediatric Indications and Dosage-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Perioperative Hypotension=====
*0.5 mg to 1 mg per every 25 pounds of body weight SUBQ or IM.
=====Mydriasis Induction=====
*For a “one application method,” Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be combined with one of the preferred rapid acting cycloplegics to produce adequate [[cycloplegia]].
<!--Off-Label Use and Dosage (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
*Phenylephrine 200 mcg (in 2 doses of 100 mcg each).<ref name="pmid4025769">{{cite journal| author=Jacobson L, Turnquist K, Masley S| title=Wolff-Parkinson-White syndrome. Termination of paroxysmal supraventricular tachycardia with phenylephrine. | journal=Anaesthesia | year= 1985 | volume= 40 | issue= 7 | pages= 657-60 | pmid=4025769 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4025769 }} </ref>
<!--Contraindications-->
|contraindications=* Phenylephrine Hydrochloride Injection should not be used in patients with severe [[hypertension]], [[ventricular tachycardia]] or in patients who are [[hypersensitive]] to it or to any of the components.
<!--Warnings-->
|warnings=====Precautions====
*Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension
:*Because of its pressor effects, phenylephrine hydrochloride can precipitate [[angina]] in patients with severe [[arteriosclerosis]] or history of [[angina]], exacerbate underlying [[heart failure]], and increase pulmonary arterial pressure.
*Bradycardia
:*Phenylephrine hydrochloride can cause severe [[bradycardia]] and decreased [[cardiac output]].
*Risk in Patients with Autonomic Dysfunction
:*The pressor response to [[adrenergic]] drugs, including phenylephrine, can be increased in patients with [[autonomic dysfunction]], as may occur with [[spinal cord injuries]].
*Skin and Subcutaneous Necrosis
:*Extravasation of phenylephrine can cause [[necrosis]] or sloughing of tissue.
*Pressor Effect with Concomitant Oxytocic Drugs
:*Oxytocic drugs potentiate the pressor effect of [[sympathomimetic]] pressor amines including phenylephrine hydrochloride, with the potential for [[hemorrhagic stroke]].
*Allergic Reactions
:*This product contains sodium metabisulfite, a sulfite that may cause [[allergic]]-type reactions, including [[anaphylactic]] symptoms and life-threatening or less severe [[asthmatic]] episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
*Peripheral and Visceral Ischemia
:*Phenylephrine hydrochloride can cause excessive peripheral and visceral [[vasoconstriction]] and [[ischemia]] to vital organs, particularly in patients with extensive [[peripheral vascular disease]].
*Renal Toxicity
:*Phenylephrine hydrochloride can increase the need for renal replacement therapy in patients with [[septic shock]]. Monitor renal function.
<!--Adverse Reactions-->
<!--Clinical Trials Experience-->
|clinicalTrials=*The following adverse reactions associated with the use of phenylephrine hydrochloride were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
[[Diaphoresis]], [[pallor]], [[piloerection]], skin blanching, skin [[necrosis]] with extravasation
=====Vascular disorders=====
[[Hypertensive crisis]]
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
<!--Drug Interactions-->
|drugInteractions=* Agonists
:*The pressor effect of phenylephrine hydrochloride is increased in patients receiving:
:**[[Monoamine oxidase inhibitors]] (MAOI), such as [[selegiline]].
:**β-adrenergic blockers
:**α-2 adrenergic agonists, such as [[clonidine]]
:**[[Steroids]]
:**[[Tricyclic antidepressants]]
:**[[Norepinephrine]] transport inhibitors, such as [[atomoxetine]]
:**[[Ergot]] alkaloids, such as methylergonovine maleate
:**Centrally-acting sympatholytic agents, such as [[guanfacine]] or [[reserpine]]
:**[[Atropine]] sulfate
*Antagonists
:*α-adrenergic blocking agents, including [[phenothiazines]] (e.g., [[chlorpromazine]]) and [[amiodarone]] block phenylephrine and are in turn blocked by phenylephrine.
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category C'''
*Animal reproduction studies have not been conducted with phenylephrine. It is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine should be given to a pregnant woman only if clearly needed.
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=*If vasopressor drugs are either used to correct [[hypotension]] or added to the [[local anesthetic]] solution, the obstetrician should be cautioned that some oxytocic drugs may cause severe persistent [[hypertension]] and that even a rupture of a cerebral blood vessel may occur during the postpartum period.
|useInNursing=*It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when phenylephrine hydrochloride is administered to a nursing woman.
|useInPed=*To combat [[hypotension]] during [[spinal anesthesia]] in children, a dose of 0.5 mg to 1 mg per 25 pounds of body weight, administered subcutaneously or intramuscularly, is recommended.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=*In patients with [[end stage renal disease]] (ESRD) undergoing [[hemodialysis]], dose-response data indicates increased responsiveness to phenylephrine. Consider using lower doses of phenylephrine hydrochloride in [[ESRD]] patients.
|useInHepaticImpair=*In patients with liver [[cirrhosis]] [Child Pugh Class A (n=3), Class B (n=5) and Class C (n=1)], dose-response data indicate decreased responsiveness to phenylephrine. Consider using larger doses than usual in hepatic impaired subjects.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
<!--Administration and Monitoring-->
|administration=*Oral
*Intravenous
*Intramuscular
*Subcutaneous
*Ophthalmic
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
<!--IV Compatibility-->
|IVCompat=*Preparing a 100 mcg/mL Solution of Bolus Intravenous Administration
:*For bolus intravenous administration, withdraw 10 mg (1 mL of a 10 mg/mL concentration) of phenylephrine injection and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP. This will yield a final concentration of 100 mcg/mL. Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
*Preparing a Solution for Continuous Intravenous Infusion
:*For continuous intravenous infusion, withdraw 10 mg (1 mL of 10 mg/mL concentration) of phenylephrine hydrochloride injection and add to 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (providing a final concentration of 20 mcg/mL).
<!--Overdosage-->
|overdose====Acute Overdose===
====Signs and Symptoms====
* Overdosage may induce ventricular [[extrasystole]] and short paroxysms of [[ventricular tachycardia]], a sensation of fullness in the head and tingling of the extremities.
*The oral LD50 in the rat is 350 mg/kg, in the mouse 120 mg/kg.
====Management====
*Should an excessive elevation of blood pressure occur, it may be immediately relieved by an α-adrenergic blocking agent (e.g. [[phentolamine]]).
===Chronic Overdose===
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
|mechAction=* Phenylephrine hydrochloride produces [[vasoconstriction]] that lasts longer than that of [[epinephrine]] and [[ephedrine]]. Responses are more sustained than those to epinephrine, lasting 20 minutes after intravenous and as long as 50 minutes after subcutaneous injection. Its action on the heart contrasts sharply with that of [[epinephrine]] and [[ephedrine]], in that it slows the heart rate and increases the stroke output, producing no disturbance in the rhythm of the pulse.
*Phenylephrine is a powerful postsynaptic alpha-receptor stimulant with little effect on the beta receptors of the heart. In therapeutic doses, it produces little if any stimulation of either the spinal cord or cerebrum. A singular advantage of this drug is the fact that repeated injections produce comparable effects.
<!--Structure-->
|structure=* Phenylephrine hydrochloride is a vasoconstrictor and pressor drug chemically related to epinephrine and ephedrine. Phenylephrine hydrochloride is a synthetic sympathomimetic agent in sterile form for parenteral injection. Chemically, phenylephrine hydrochloride is (-)-m-Hydroxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride, and has the following structural formula:
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
*Each mL contains: Phenylephrine Hydrochloride 10 mg; Sodium Chloride 3.5 mg; Sodium Citrate Dihydrate 4 mg; Citric Acid Monohydrate 1 mg; Sodium Metabisulfite 2 mg; Water for Injection q.s. pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid if necessary. pH 3.0-6.5.
<!--Pharmacodynamics-->
|PD=*The predominant actions of phenylephrine are on the [[cardiovascular]] system. Parenteral administration causes a rise in systolic and diastolic pressures in man and other species. Accompanying the pressor response to phenylephrine is a marked reflex [[bradycardia]] that can be blocked by [[atropine]]; after [[atropine]], large doses of the drug increase the heart rate only slightly. In man, [[cardiac output]] is slightly decreased and peripheral resistance is considerably increased. Circulation time is slightly prolonged, and venous pressure is slightly increased; venous constriction is not marked. Most vascular beds are constricted; renal splanchnic, cutaneous and limb blood flows are reduced but coronary blood flow is increased. Pulmonary vessels are constricted, and pulmonary arterial pressure is raised.
'''Phenylephrine''' is a selective [[Alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]] [[agonist]] used primarily as a [[decongestant]], as an agent to dilate the [[pupil]], and to increase [[blood pressure]]. Phenylephrine is marketed as a substitute for the decongestant [[pseudoephedrine]], though clinical studies differ regarding its effectiveness in this role.
*The drug is a powerful [[vasoconstrictor]] with properties very similar to those of [[norepinephrine]] but almost completely lacking the [[chronotropic]] and [[inotropic]] actions on the heart. Cardiac irregularities are seen only very rarely even with large doses.
==Uses==
<!--Pharmacokinetics-->
===Decongestant===
|PK=*Following an intravenous infusion of phenylephrine hydrochloride, the effective half-life was approximately 5 minutes. The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments. The average total serum clearance (2095 mL/min) was close to one-third of the cardiac output.
Phenylephrine is used as a decongestant sold as an oral medicine, as a [[nasal spray]], or as eye drops. It is now the most common [[Over-the-counter drug|over-the-counter]] [[decongestant]] in the United States; [[oxymetazoline]] is a more common nasal spray.
Oral phenylephrine is extensively [[metabolism|metabolised]] by [[monoamine oxidase]],<ref name = DB>http://www.drugbank.ca/drugs/DB00388#identification</ref> an [[enzyme]] that is present in the intestinal wall and in the liver. Compared to intravenous pseudoephedrine, it has a reduced and variable [[bioavailability]]; only up to 38%.<ref name = DB/><ref>[http://www.medsafe.govt.nz/Profs/Class/mccMin25Nov2004.htm NZ Medicines and Medical Devices Safety Authority recommendation on phenylephrine] (November 2004)</ref> Because phenylephrine is a selective α-[[adrenergic receptor]] agonist it does not cause the release of endogenous [[Norepinephrine|noradrenaline]]. Nor does it increase the rate ([[chronotropy]]) and strength ([[inotropy]]) of heart contractions, as pseudoephedrine does.<ref>http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72348406-e74f-46c5-b93d-34d07cffe1fd</ref> Phenylephrine may cause side effects such as headache, reflex bradycardia, excitability, restlessness and cardiac arrhythmias.<ref>http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72348406-e74f-46c5-b93d-34d07cffe1fd</ref>
*A mass balance study showed that phenylephrine is extensively metabolized by the liver with only 12% of the dose excreted unchanged in the urine. Deamination by monoamino oxidase is the primary metabolic pathway resulting in the formation of the major metabolite (m-hydroxymandelic acid) which accounts for 57% of the total administered dose.
Phenylephrine is used as a replacement for pseudoephedrine in decongestant medicines due to pseudoephedrine's use in the illicit manufacture of methamphetamine. Its efficacy as an oral decongestant has been questioned, with multiple studies not being able to come to an agreement. Whereas pseudoephedrine causes both vasoconstriction and increase of mucociliary clearance through its nonspecific adrenergic activity, phenylephrine's selective α-adrenergic agonism causes vasoconstriction alone, creating a difference in their methods of action.
<!--Nonclinical Toxicology-->
|nonClinToxic=*No long-term animal studies have been done to evaluate the potential of phenylephrine in these areas.
As a nasal spray, phenylephrine is available in 1% and 0.5% concentrations. It may cause [[rhinitis medicamentosa|rebound congestion]], similar to oxymetazoline.
<!--Clinical Studies-->
|clinicalStudies=*Increases in systolic and mean blood pressure following administration of phenylephrine were observed in 42 literature-based studies in the perioperative setting, including 26 studies where phenylephrine was used in low-risk (ASA 1 and 2) pregnant women undergoing neuraxial [[anesthesia]] during [[cesarean delivery]], 3 studies in non-obstetric surgery under neuraxial anesthesia, and 13 studies in patients undergoing surgery under [[general anesthesia]]. Mean arterial blood pressure increases were also observed in two double-blind, active-controlled studies in patients with [[septic shock]].
===Hemorrhoid discomfort===
<!--How Supplied-->
This medication is used to temporarily relieve swelling, burning, pain, and itching caused by hemorrhoids. It works by temporarily narrowing the blood vessels in the area. This effect decreases swelling and discomfort. Some products may also contain substances (e.g., cocoa butter, hard fat, mineral oil, shark liver oil) that form a protective barrier to prevent too much irritating contact with stool.<ref>http://www.webmd.com/drugs/drug-76444-phenylephrine+HCl+Rect.aspx?drugid=76444&drugname=phenylephrine+HCl+Rect</ref>
|howSupplied=*Phenylephrine Hydrochloride Injection, USP, is supplied as follows:
:*NDC 0641-6142-25: 1 mL single dose vials packaged in cartons containing 25 vials per carton.
===Mydriatic===
*Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Keep covered in carton until time of use. For single use only. Discard unused portion.
Phenylephrine is used as an eye drop to dilate the pupil to facilitate visualization of the retina. It is often used in combination with [[tropicamide]] as a synergist when tropicamide alone is not sufficient. Narrow-angle [[glaucoma]] is a [[contraindication]] to phenylephrine use. As a [[mydriasis|mydriatic]], it is available in 2.5% and 10% minims.
===Vasopressor===
<!--Patient Counseling Information-->
Phenylephrine is commonly used as a [[vasopressor]] to increase the blood pressure in unstable patients with [[hypotension]], especially resulting from septic shock. Such use is common in anesthesia or critical-care practices; it is especially useful in counteracting the hypotensive effect of [[epidural]] and [[subarachnoid]] [[anesthetics]], as well as the vasodilating effect of bacterial toxins and the inflammatory response in [[sepsis]] and [[systemic inflammatory response syndrome]]. It has the advantage of not being [[inotrope|inotropic]] or [[chronotropic]], so it strictly elevates the blood pressure without increasing the heart rate or contractility (reflex [[bradycardia]] may result from the blood pressure increase, however). This is especially useful if the heart is already tachycardic and/or has a [[cardiomyopathy]]. The elimination half life of phenylephrine is about 2.5 to 3.0 hours.
|fdaPatientInfo=*Inform patients, families, or caregivers that the primary side effect of phenylephrine is [[hypertension]] and rarely, [[hypertensive crisis]]. Patients may experience [[bradycardia]] (slow heart rate), which in some cases may produce heart block or other [[cardiac arrhythmias]], extra ventricular beats, [[myocardial ischemia]] in patients with underlying [[cardiac disease]], and [[pulmonary edema]] (fluid in the lungs) or [[rales]]. Common, less serious symptoms include the following:
:*[[Chest pain]]
:*Skin or tissue damage if the drug leaks out of the [[venous catheter]] into the surrounding tissue
:*[[Headache]], nervousness, [[tremor]], [[numbness]]/tingling ([[paresthesias]]) in hands or feet
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
<!--Brand Names-->
|brandNames=* PHENYLEPHRINE HYDROCHLORIDE®<ref>{{Cite web | title = PHENYLEPHRINE HYDROCHLORIDE phenylephrine hydrochloride injection | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1a7ab4b-0afe-4463-a039-5be0323cf2f7 }}</ref>
<!--Look-Alike Drug Names-->
|lookAlike=<!--Drug Shortage Status-->
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}02.png
}}
{{LabelImage
|fileName={{PAGENAME}}03.png
}}
{{LabelImage
|fileName={{PAGENAME}}04.png
}}
{{LabelImage
|fileName={{PAGENAME}}05.png
}}
<!--Pill Image-->
Because of its vasoconstrictive effect, phenylephrine (Neo-Synephrine) can cause severe necrosis if it infiltrates the surrounding tissues. Because of this, it should be given through a central line if at all possible. Damage may be prevented or mitigated by infiltrating the tissue with the alpha blocker phentolamine by subcutaneous injection.<ref>Cooper, B. E. (2008). Review and Update on Inotropes and Vasopressors. AACN Advanced Critical Care, 19, 5–15.</ref>
Phenylephrine hydrochloride at 0.25% is used as a vasoconstrictor in some [[suppository]] formulations.
===Detumescent===
<!--Label Display Image-->
Phenylephrine is used by urologists to abort [[priapism]]. It is diluted significantly and injected directly into the [[Corpus cavernosum penis|corpora cavernosa]]. The mechanism of action is to cause constriction of the blood vessels entering into the penis, thus breaking the pathophysiologic cycle that continues the priapism.
==Side effects==
The primary side effect of phenylephrine is [[hypertension]]. Patients with hypertension are typically advised to avoid products containing it. [[Prostatic hyperplasia]] can also be symptomatically worsened by use, and chronic use can lead to rebound [[hyperemia]].<ref name=pharmnemonics>{{Cite book|author=Shen, Howard|title=Illustrated Pharmacology Memory Cards: PharMnemonics|year=2008|publisher=Minireview|isbn=1-59541-101-1|page=3}}</ref> Patients with a history of anxiety or panic disorders, or on anticonvulsant medication for epilepsy should not take this substance. The drug interaction might produce seizures. Some patients have been shown to have an upset stomach, severe abdominal cramping, and vomiting issues connected to taking this drug.
Because this medication is a [[sympathomimetic]] amine, it can also increase contractility force and increase output to the cardiac muscle. In other words, phenylephrine mimics norepinephrine binding to α-adrenoreceptors and can cause increased heart rate.
Extended use may cause [[rhinitis medicamentosa]], a condition of [[Rebound effect|rebound]] [[nasal congestion]].
==Substitute for pseudoephedrine==
Pseudoephedrine and phenylephrine are both used as decongestants; and, until recently, [[pseudoephedrine]] was much more commonly available in the United States. This has changed because provisions of the [[Combat Methamphetamine Epidemic Act of 2005]] placed restrictions on the sale of pseudoephedrine products to prevent the [[clandestine chemistry|clandestine manufacture]] of [[methamphetamine]]. Since 2004, phenylephrine has been increasingly marketed as a substitute for pseudoephedrine; some manufacturers have changed the active ingredients of products to avoid the restrictions on sales.<ref name="HeraldTribune"/> Phenylephrine has been off [[patent]] for some time, and many generic brands are available.
==Questions about effectiveness==
Pharmacists Leslie Hendeles and Randy Hatton of the [[University of Florida]] suggested in 2006 that oral phenylephrine is ineffective as a decongestant at the 10-mg dose used, arguing that the studies used for the regulatory approval of the drug in the United States in 1976 were inadequate to prove effectiveness at the 10-mg dose, and safety at higher doses.<ref name="Hendeles2006">{{cite journal|author=Heldeles, L. and Hatton, R.|title=Oral phenylephrine: An ineffective replacement for pseudoephedrine?|journal=Journal of Allergy and Clinical Immunology|volume=118|issue=1|pages=279–280|pmid=16815167|year=2006|doi=10.1016/j.jaci.2006.03.002}}</ref> Other pharmacists have expressed concerns over phenylephrine's effectiveness as a nasal decongestant,<ref name="UFL1">{{cite web
|url=http://news.ufl.edu/2006/07/19/decongensant/
|author=University of Florida
|title=UF researchers question effectiveness of decongestant
|date=2006-07-19
|accessdate=2008-03-15}}</ref> and other clinicians have indicated concern for regulatory actions that reduced the availability of pseudoephedrine.<ref name="pmid16484253">{{cite web|author=Eccles R|title=Phenylephrine an ineffective replacement for pseudoephedrine in response to the methamphetamine problem in the USA|url=http://www.bmj.com/cgi/eletters/332/7538/382-b|date=May 2006|publisher=BMJ}}<br />'''Rapid Response to'''<br />{{cite journal|author=Tanne JH|title=Methamphetamine epidemic hits middle America|journal=BMJ|volume=332|issue=7538|pages=382|date=February 2006|pmid=16484253|doi=10.1136/bmj.332.7538.382-b|url=|pmc=1370997}}</ref><ref name="BJM">{{cite journal|author=Eccles, R.|doi=10.1111/j.1365-2125.2006.02833.x|title=Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse|journal=British Journal of Clinical Pharmacology|volume=63|pages=10–14|pmid=17116124|year=2007|issue=1|pmc=2000711}} (January 2007)</ref> A subsequent meta-analysis by the same researchers concluded that the evidence for its effectiveness is insufficient,<ref name="Annals">{{cite journal|author=Hatton, R.C. et al.|url=http://www.theannals.com/cgi/content/abstract/aph.1H679v1|title=Efficacy and Safety of Oral Phenylephrine: A Systematic Review and Meta-Analysis|journal=Annals of Pharmacotherapy|volume=41|pages=381–390|doi=10.1345/aph.1H679|pmid=17264159|year=2007|format=abstract|issue=3}}(published online Jan 2007)</ref> though another meta-analysis published shortly thereafter by researchers from [[GlaxoSmithKline]] found the standard 10-mg dose to be significantly more effective than a placebo.<ref name="GSK">{{cite pmid|17692721}}{{medrs|date=August 2012}}</ref> Additionally, two studies published in 2009 examined the effects of phenylephrine on symptoms of [[allergic rhinitis]] by exposing sufferers to pollen in a controlled, indoor environment. Neither study was able to distinguish between the effects of phenylephrine or a placebo.<ref name="danzig09">{{Cite pmid|19230461}}</ref><ref name="yao09">{{Cite pmid|19441605}}</ref> Pseudoephedrine<ref name="danzig09" /> and [[loratadine]]-[[montelukast]] therapy<ref name="yao09" /> were found to be significantly more effective than both phenylephrine and placebo.
The [[Food and Drug Administration]] has stood by its 1976 approval of phenylephrine for nasal congestion as the debate continues.<ref name="HeraldTribune">{{cite news|author=Hilenmeyer, K.|url=http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/FP/20070130/HEALTHMATTERS/70129001/1025/NEWS06|title=All stuffed up|publisher=Southwest Florida Herald-Tribune|date=30 January 2007}}</ref>
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Phenylephrine (injection) is an alpha-1 adrenergic receptor agonist that is FDA approved for the treatment of hypotension, glaucoma, mydriasis induction, and uveitis. Common adverse reactions include nausea, vomiting, headache, and nervousness.
50 mcg to 250 mcg by intravenous bolus administration. The most frequently reported initial bolus dose is 50 mcg or 100 mcg.
0.5 mcg/kg/min to 1.4 mcg/kg/min by intravenous continuous infusion, titrated to blood pressure goal.
Septic or Other Vasodilatory Shock
No bolus.
0.5 mcg/kg/min to 6 mcg/kg/min by intravenous continuous infusion, titrated to blood pressure goal. Doses above 6 mcg/kg/min do not show significant incremental increase in blood pressure.
Uveitis
Posterior Synechiae: Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be used in patients with uveitis when synechiae are present or may develop. The formation of synechiae may be prevented by the use of this solution and atropine or other cycloplegics to produce wide dilation of the pupil. For recently formed posterior synechiae one drop of Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be applied to the upper surface of the cornea and be repeated as necessary, not to exceed three times. Treatment may be continued the following day, if necessary. Atropine sulfate and the application of hot compresses should also be used if indicated.
Glaucoma
Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be used with miotics in patients with open angle glaucoma. It reduces the difficulties experienced by the patient because of the small field produced by miosis, and still it permits and often supports the effect of the miotic in lowering the intraocular pressure in open angle glaucoma. Hence, there may be marked improvement in visual acuity after using Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% in conjunction with miotic drugs.
Mydriasis Induction
Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be used effectively to increase mydriasis with homatropine hydrobromide, cyclopentolate hydrochloride, tropicamide hydrochloride and atropine sulfate.
One drop of the preferred cycloplegic is placed in each eye, followed in 5 minutes by one drop of Phenylephrine Hydrochloride Ophthalmic Solution, 2.5%. Since adequate cycloplegia is achieved at different time intervals after the instillation of the necessary number of drops, different cycloplegics will require different waiting periods to achieve adequate cycloplegia.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Phenylephrine (injection) in adult patients.
Non–Guideline-Supported Use
Hypotension, During anesthesia; Prophylaxis
In women undergoing elective cesarean section with spinal anesthesia, phenylephrine reduced the incidence of hypotension when used with ephedrine as prophylaxis.[1]
1 mg phenylephrine bolus followed by continuous intracavernosal phenylephrine infusion of 2 mg/hour.[4]
Regional anesthesia; Adjunct
Phenylephrine 0.125% to combinations of tetracaine 0.5% plus glucose 7.5% or 0.75%.[5]
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Perioperative Hypotension
0.5 mg to 1 mg per every 25 pounds of body weight SUBQ or IM.
Mydriasis Induction
For a “one application method,” Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% may be combined with one of the preferred rapid acting cycloplegics to produce adequate cycloplegia.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Phenylephrine (injection) in pediatric patients.
Non–Guideline-Supported Use
Paroxysmal supraventricular tachycardia
Phenylephrine 200 mcg (in 2 doses of 100 mcg each).[6]
Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension
Because of its pressor effects, phenylephrine hydrochloride can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure.
Extravasation of phenylephrine can cause necrosis or sloughing of tissue.
Pressor Effect with Concomitant Oxytocic Drugs
Oxytocic drugs potentiate the pressor effect of sympathomimetic pressor amines including phenylephrine hydrochloride, with the potential for hemorrhagic stroke.
Allergic Reactions
This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Phenylephrine hydrochloride can increase the need for renal replacement therapy in patients with septic shock. Monitor renal function.
Adverse Reactions
Clinical Trials Experience
The following adverse reactions associated with the use of phenylephrine hydrochloride were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
α-adrenergic blocking agents, including phenothiazines (e.g., chlorpromazine) and amiodarone block phenylephrine and are in turn blocked by phenylephrine.
Animal reproduction studies have not been conducted with phenylephrine. It is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine should be given to a pregnant woman only if clearly needed.
Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Phenylephrine (injection) in women who are pregnant.
Labor and Delivery
If vasopressor drugs are either used to correct hypotension or added to the local anesthetic solution, the obstetrician should be cautioned that some oxytocic drugs may cause severe persistent hypertension and that even a rupture of a cerebral blood vessel may occur during the postpartum period.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when phenylephrine hydrochloride is administered to a nursing woman.
Pediatric Use
To combat hypotension during spinal anesthesia in children, a dose of 0.5 mg to 1 mg per 25 pounds of body weight, administered subcutaneously or intramuscularly, is recommended.
Geriatic Use
There is no FDA guidance on the use of Phenylephrine (injection) with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Phenylephrine (injection) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Phenylephrine (injection) with respect to specific racial populations.
Renal Impairment
In patients with end stage renal disease (ESRD) undergoing hemodialysis, dose-response data indicates increased responsiveness to phenylephrine. Consider using lower doses of phenylephrine hydrochloride in ESRD patients.
Hepatic Impairment
In patients with liver cirrhosis [Child Pugh Class A (n=3), Class B (n=5) and Class C (n=1)], dose-response data indicate decreased responsiveness to phenylephrine. Consider using larger doses than usual in hepatic impaired subjects.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Phenylephrine (injection) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Phenylephrine (injection) in patients who are immunocompromised.
Administration and Monitoring
Administration
Oral
Intravenous
Intramuscular
Subcutaneous
Ophthalmic
Monitoring
There is limited information regarding Monitoring of Phenylephrine (injection) in the drug label.
IV Compatibility
Preparing a 100 mcg/mL Solution of Bolus Intravenous Administration
For bolus intravenous administration, withdraw 10 mg (1 mL of a 10 mg/mL concentration) of phenylephrine injection and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP. This will yield a final concentration of 100 mcg/mL. Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
Preparing a Solution for Continuous Intravenous Infusion
For continuous intravenous infusion, withdraw 10 mg (1 mL of 10 mg/mL concentration) of phenylephrine hydrochloride injection and add to 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (providing a final concentration of 20 mcg/mL).
Overdosage
Acute Overdose
Signs and Symptoms
Overdosage may induce ventricular extrasystole and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities.
The oral LD50 in the rat is 350 mg/kg, in the mouse 120 mg/kg.
Management
Should an excessive elevation of blood pressure occur, it may be immediately relieved by an α-adrenergic blocking agent (e.g. phentolamine).
Chronic Overdose
There is limited information regarding Chronic Overdose of Phenylephrine (injection) in the drug label.
Phenylephrine hydrochloride produces vasoconstriction that lasts longer than that of epinephrine and ephedrine. Responses are more sustained than those to epinephrine, lasting 20 minutes after intravenous and as long as 50 minutes after subcutaneous injection. Its action on the heart contrasts sharply with that of epinephrine and ephedrine, in that it slows the heart rate and increases the stroke output, producing no disturbance in the rhythm of the pulse.
Phenylephrine is a powerful postsynaptic alpha-receptor stimulant with little effect on the beta receptors of the heart. In therapeutic doses, it produces little if any stimulation of either the spinal cord or cerebrum. A singular advantage of this drug is the fact that repeated injections produce comparable effects.
Structure
Phenylephrine hydrochloride is a vasoconstrictor and pressor drug chemically related to epinephrine and ephedrine. Phenylephrine hydrochloride is a synthetic sympathomimetic agent in sterile form for parenteral injection. Chemically, phenylephrine hydrochloride is (-)-m-Hydroxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride, and has the following structural formula:
Each mL contains: Phenylephrine Hydrochloride 10 mg; Sodium Chloride 3.5 mg; Sodium Citrate Dihydrate 4 mg; Citric Acid Monohydrate 1 mg; Sodium Metabisulfite 2 mg; Water for Injection q.s. pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid if necessary. pH 3.0-6.5.
Pharmacodynamics
The predominant actions of phenylephrine are on the cardiovascular system. Parenteral administration causes a rise in systolic and diastolic pressures in man and other species. Accompanying the pressor response to phenylephrine is a marked reflex bradycardia that can be blocked by atropine; after atropine, large doses of the drug increase the heart rate only slightly. In man, cardiac output is slightly decreased and peripheral resistance is considerably increased. Circulation time is slightly prolonged, and venous pressure is slightly increased; venous constriction is not marked. Most vascular beds are constricted; renal splanchnic, cutaneous and limb blood flows are reduced but coronary blood flow is increased. Pulmonary vessels are constricted, and pulmonary arterial pressure is raised.
The drug is a powerful vasoconstrictor with properties very similar to those of norepinephrine but almost completely lacking the chronotropic and inotropic actions on the heart. Cardiac irregularities are seen only very rarely even with large doses.
Pharmacokinetics
Following an intravenous infusion of phenylephrine hydrochloride, the effective half-life was approximately 5 minutes. The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments. The average total serum clearance (2095 mL/min) was close to one-third of the cardiac output.
A mass balance study showed that phenylephrine is extensively metabolized by the liver with only 12% of the dose excreted unchanged in the urine. Deamination by monoamino oxidase is the primary metabolic pathway resulting in the formation of the major metabolite (m-hydroxymandelic acid) which accounts for 57% of the total administered dose.
Nonclinical Toxicology
No long-term animal studies have been done to evaluate the potential of phenylephrine in these areas.
Clinical Studies
Increases in systolic and mean blood pressure following administration of phenylephrine were observed in 42 literature-based studies in the perioperative setting, including 26 studies where phenylephrine was used in low-risk (ASA 1 and 2) pregnant women undergoing neuraxial anesthesia during cesarean delivery, 3 studies in non-obstetric surgery under neuraxial anesthesia, and 13 studies in patients undergoing surgery under general anesthesia. Mean arterial blood pressure increases were also observed in two double-blind, active-controlled studies in patients with septic shock.
How Supplied
Phenylephrine Hydrochloride Injection, USP, is supplied as follows:
NDC 0641-6142-25: 1 mL single dose vials packaged in cartons containing 25 vials per carton.
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Keep covered in carton until time of use. For single use only. Discard unused portion.
Storage
There is limited information regarding Phenylephrine (injection) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Phenylephrine (injection)
|?Pill Name
|?Drug Name
|?Pill Ingred
|?Pill Imprint
|?Pill Dosage
|?Pill Color
|?Pill Shape
|?Pill Size (mm)
|?Pill Scoring
|?NDC
|?Drug Author
|format=template
|template=DrugPageImages
|mainlabel=-
|sort=Pill Name
}}
01.png){kind=link}